Cover Story
Conversation with The Cancer LetterFree
After a decade of near-absence from the US market, the AstraZeneca drug Iressa (gefitinib) is back.
In Brief
Drugs & Targets
Trending Stories
- As Trump’s second term nears, Republican support for NIH is at a low point
By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research - As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer
- Trump 2016: A look back at the 45th president’s impact on oncology
- Cedars-Sinai spearheads first national certification program for COE staff at cancer centers
- Menin inhibitors emerge as new treatment for advanced AML
- Patient navigation benefits health systems, improves care
Initial data presented at the White House come a year after CMS payment began